《大行報告》野村上調康寧傑瑞製藥-B(09966.HK)目標價至28.8元 評級「買入」
野村發表研報指,康寧傑瑞製藥(09966.HK)於美國臨床腫瘤學會年會發布產品KN046及KN026的研究結果。
數據顯示,KN046作為一線療法,用於治療鱗狀非小細胞肺癌及胰臟癌的成功率估算已由50%提升至75%及80%,而KN026作為二線療法治療胃癌或胃食管結合部癌及乳癌的成功率亦由25%提升至50%。
野村表示,期望KN046的第三期臨床試驗可進一步改善療效及得出更安全數據,包括對治療相關不良事件(TRAE)及作出更具體描述,又指KN026的臨床數據及安全性均向好。根據研究結果,野村對康寧傑瑞維持「買入」評級,目標價由25.1元上調15%至28.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.